Rani Therapeutics
Rani Therapeutics has developed a disruptive technology for the oral delivery of biologics, aiming to replace painful injections with their innovative RaniPill platform.
Company Overview
Rani Therapeutics is headquartered at 2051 Ringwood Ave, San Jose, CA 95131. The company has developed a disruptive technology focused on the oral delivery of biologics. This innovative approach aims to replace painful injections, providing a more comfortable alternative for patients with chronic conditions. Rani Therapeutics' technology has demonstrated high reliability, safety, and tolerability in multiple preclinical and clinical studies.
RaniPill Platform
The RaniPill platform is a pioneering technology that enables the oral delivery of proteins, peptides, and antibodies. This capsule is designed to navigate through the stomach and inject the drug directly into the intestinal wall, ensuring minimal discomfort and high bioavailability. The bioavailability of RaniPill-delivered products is comparable to or better than subcutaneous injections, making it a game-changer in the treatment of various conditions.
Targeted Medical Conditions
Rani Therapeutics has a robust pipeline targeting several medical conditions, including osteoporosis, psoriatic arthritis, and diabetes. One of its notable developments, RT-111, an oral Ustekinumab Biosimilar, has shown positive results in Phase 1 clinical trials. By focusing on chronic conditions that require frequent and long-term medication, Rani Therapeutics aims to enhance patient compliance and improve their quality of life.
Research and Development
Rani Therapeutics is committed to rigorous research and development. The company has conducted numerous preclinical and clinical studies to validate the safety, reliability, and efficacy of its RaniPill platform. These studies have shown that the oral delivery system not only meets high safety standards but also provides effective bioavailability, similar to or exceeding that of traditional subcutaneous injections.
Patent Portfolio
Rani Therapeutics holds a strong patent position covering both its innovative RaniPill platform and the combination of drugs with the platform. This extensive patent portfolio supports the company's leadership in the field of oral biologics delivery and safeguards its proprietary technology against competition. This strategic patenting reinforces the company's potential for long-term growth and significant impact on the healthcare industry.